2024届IB成绩捷报 IB成绩放榜,根据IBO官方公布的官方数据显示,今年全球IBDP平均分30.32分,上海耀中自豪地宣布2024届学子再创佳绩,平均分35.1,不仅成绩远远高于全球平均分,且有1名学生获IB满分,20%学子获得42分及以上高分,IB文凭通过率高达98%,其中50%的学生获IB双语文凭,上海耀中多语、多元文化视野的教育优势有目共...
good IB results again. 2 students got a perfect score of 45. 31% of the candidates scored above 40. In the ten years since its establishment, DSI has taken the curriculum and faculty as the starting point and has...
Results: The PP‐NRS demonstrated acceptable test–retest reliability (ICC: 0.86–0.89). Known‐group evidence demonstrated that PP‐NRS scores could discriminate between different degrees of disease severity. Convergent validity was supported by significant correlation coefficients between the PP‐NRS and...
Old Captain, Narcolepsia and 4IB Records proudly present a re-release of a masterpiece of experimental electronic music commemorating 35 years since its first release in 1987! “She was unique. Had a bad time in her childhood, her later years were never comfortable. But somehow she got an ...
2020;396(10246):255-266. doi:10.1016/S0140-6736(20)30732-7 PubMedGoogle ScholarCrossref 19. Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized...
Jun 12, 2019New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR Feb 19, 2019AbbVie Announces New Drug Application Accepted for Priority Review by FDA for Upadacitinib for Treatment of Moderate to Se...
This release contains forward-looking information about CIBINQO (abrocitinib), including its potential benefits, an approval in the U.S. and anticipated product availability, that involves substantial risks and uncertainties that could cause actual results to differ materially from those e...
Deucravacitinib (SOTYKTU™) is a first-in-class, highly selective, oral tyrosine kinase 2 (TYK2) inhibitor. It acts via an allosteric mechanism, bindi
making forward-looking statements, such statements are subject to risks and uncertainties that could cause Vertex's actual results to vary materially. These risks and uncertainties include, among other things, the risks that clinical trials for merimepodib or VX-950 may not proceed as ...
Since August 2020, there has been a Cawbird "unstable" package built on the Open Build Service. These packages are intended for users who can't build Cawbird from source but want to test new features.Do not use the unstable release unless you are testing new features and understand the ...